Results 161 to 170 of about 3,032,107 (315)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Using mass spectrometry for robust identity release testing in a global quality control network. [PDF]

open access: yesMAbs
Leibe S   +13 more
europepmc   +1 more source

Quality controlled turbulent fluxes of co-emitted species (CO, NOx, CH4, N2O) from each city (CHHar, FR-Rmv, DE-Opd)

open access: green
Rainer Hilland   +9 more
openalex   +1 more source

Concise Review: Molecular Cytogenetics and Quality Control: Clinical Guardians for Pluripotent Stem Cells [PDF]

open access: gold, 2018
Leili Rohani   +5 more
openalex   +1 more source

Quality Control for Lignin and Gelatin Microcapsules Loaded with Orange Essential Oil

open access: gold, 2021
Maria Clara Santana Aguiar   +6 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy